In situ vaccination of CMP-001 TLR-9 agonist in combination with anti-PD-1 therapy induced durable HNSCC tumor regression at injected tumors and distant ones and significantly prolonged survival compared with anti-PD-1 therapy alone [29], indicating the higher effectiveness of local administration compared to systemic administration. The gene discussed is TLR9; the disease is neoplasm.